Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorproguanil SCHEMBL1000272 | 0.98 | SMN1; SMN2 (0.45) | EPHX1EPHX2SMN1; SMN2CYP3A4APEX1 | |
| SCHEMBL1983057 | 0.92 | EPHX1 (0.50) | EPHX1EPHX2SMN1; SMN2CYP3A4APEX1 | |
| SCHEMBL13584612 | 0.87 | EPHX1 (0.59) | EPHX1EPHX2CYP3A4APEX1SLC6A2 | |
| SCHEMBL29518499 | 0.87 | EPHX1 (0.59) | EPHX1EPHX2CYP3A4APEX1SLC6A2 | |
| Hydrochloric Acid SCHEMBL13584366 | 0.85 | EPHX1 (0.57) | EPHX1EPHX2CYP3A4APEX1SLC6A2 | |
| Chlorproguanil SCHEMBL18548846 | 0.84 | PKM (0.43) | EPHX1EPHX2SMN1; SMN2CA2CA9 | |
| Proguanil SCHEMBL45726 | 0.82 | LMNA (0.41) | EPHX1SMN1; SMN2SLC6A2ADRA2ADRD1 | |
| Proguanil SCHEMBL218859 | 0.81 | LMNA (0.40) | EPHX1SMN1; SMN2SLC6A2ADRA2ADRD1 | |
| Proguanil SCHEMBL2543837 | 0.81 | LMNA (0.40) | EPHX1SMN1; SMN2SLC6A2ADRA2ADRD1 | |
| SCHEMBL20315920 | 0.81 | SMN1; SMN2 (0.49) | EPHX1EPHX2SMN1; SMN2CYP3A4APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1504 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144251-A1 | ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF | POLYAMYNA NANOTECH INC. (CA) | 2026-05-28 | — | — | US | claimed |
| US-20250388603-A1 | ANTIMALARIAL COMPOUNDS | SCRIPPS RESEARCH INST (US) | 2025-12-25 | — | — | US | claimed |
| WO-2025244856-A1 | METHODS AND COMPOSITIONS RELATING TO ELQ COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-11-27 | — | — | WO | claimed |
| EP-3625238-B1 | NOVEL SPIRO-LACTAM COMPOUNDS, PROCESS AND USES THEREOF | UNIV DE COIMBRA (PT) | 2025-11-26 | — | — | EP | claimed |
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | claimed |
| EP-4574143-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | Universität Regensburg (DE) | 2025-06-25 | — | — | EP | claimed |
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-19 | — | — | US | claimed |
| US-20250082685-A1 | METHODS FOR ATTENUATING VIRAL INFECTION AND FOR TREATING LUNG INJURY | Spiritus Therapeutics, Inc. (US) | 2025-03-13 | — | — | US | claimed |
| EP-4516322-A2 | RESIDENCE STRUCTURES AND RELATED METHODS | Massachusetts Institute of Technology (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4499631-A1 | PYRAZINE AMIDE DERIVATIVES | Novartis AG (CH) | 2025-02-05 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1095050-A1 | PHOSPHOROUS ORGANIC COMPOUNDS AND THEIR USE | Jomaa, Hassan (DE) | 2001-05-02 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| EP-1071409-A2 | USE OF ORGANOPHOSPHORIC COMPOUNDS FOR THE THERAPEUTIC AND PREVENTATIVE TREATMENT OF INFECTIONS | Jomaa, Hassan (DE) | 2001-01-31 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000044359-A2 | UTILISATION OF THIADIZOLE DERIVATIVES FOR THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2000-08-03 | — | — | WO | claimed |
| WO-2000044358-A2 | USE OF PHOSPHORORGANIC COMPOUNDS FOR THE PROPHYLACTIC AND THERAPEUTICAL TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2000-08-03 | — | — | WO | claimed |
| WO-2000016757-A2 | USE OF ORGANOPHOSPHOROUS COMPOUNDS FOR PRODUCING MEDICAMENTS FOR THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF INFECTIONS OR AS A FUNGICIDE, BACTERICIDE OR HERBICIDE FOR PLANTS | JOMAA PHARMAKA GMBH (DE) | 2000-03-30 | — | — | WO | claimed |
| WO-2000004031-A1 | PHOSPHOROUS ORGANIC COMPOUNDS AND THEIR USE | JOMAA HASSAN (DE) | 2000-01-27 | — | — | WO | claimed |
| WO-1999052515-A2 | USE OF ORGANOPHOSPHORIC COMPOUNDS FOR THE THERAPEUTIC AND PREVENTATIVE TREATMENT OF INFECTIONS | HASSAN JOMAA (DE) | 1999-10-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144251-A1 | ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF | KLF10, SLC11A2, SLC7A11 | EPHX1 4865/4885EPHX2 4681/4885SMN1; SMN2 2763/4885 |
| US-20250388603-A1 | ANTIMALARIAL COMPOUNDS | HCCS, CYC1, NHERF1 | EPHX1 1102/4885EPHX2 1230/4885SMN1; SMN2 2622/4885 |
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | SIRT5, GLS2, ARG2 | EPHX1 1552/4885EPHX2 1765/4885SMN1; SMN2 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.